The Food and Drug Administration recently lifted a partial hold on Geron's (NASDAQ:GERN) imetelstat for a trial in myelofibrosis. The drug has shown great efficacy data so far, sending myelofibrosis patients into complete remission -- something Incyte's (NASDAQ:INCY) Jakafi, the only approved drug for myelofibrosis, can't do.
But the trial that was reinstated was just an investigator-sponsored trial. To release the clinical hold on company-run trials in essential thrombocythemia, polycythemia vera, and multiple myeloma, Geron has to present more preclinical data and analyze the clinical data to convince the FDA that imetelstat isn't causing permanent liver damage.
Watch the video below for more thoughts from senior biotech specialist Brian Orelli and health-care analyst David Williamson on Geron's prospects and whether Incyte has anything to worry about.
Brian Orelli, David Williamson, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Geron Corporation's 13% Drop in 2017, Explained
Uncertainty regarding Geron's partnership with Johnson & Johnson takes shareholders for a wild ride.
3 Stocks That Feel Like Microsoft in 1986
Two specialized small-cap drug developers, and a financial holding company share similar traits to software giant Microsoft from three decades ago.
5 Biotech Buyout Candidates for 2018
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.